Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life. Casey Butrus, PharmD: Dr Cameron, what’s the typical onset of action when you’re looking at a ...
Please provide your email address to receive an email when new articles are posted on . Ruxolitinib-treated patients achieved greater differences from baseline in itch intensity vs. vehicle. More ...
Please provide your email address to receive an email when new articles are posted on . Roflumilast cream 0.15% showed rapid itch reduction within 24 hours of first application. More than 40% of ...
How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab's fast onset of ...
STAMFORD, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of ...
Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...
Reviewed By Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina Coping with the symptoms ...
- VTAMA® (tapinarof) cream, 1% demonstrated early, significant, and meaningful achievement of both no-to-minimal itch (mean weekly PP-NRS≤1) and sleep improvement in ADORING 1 and ADORING 2. - 31.4% ...
SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback